Yearly Archives: 2016

VIDEO: News Spotlight on VGXI’s Role in Production of a Zika DNA Vaccine

On July 13th, 2016 VGXI was featured on KPRC Channel 2 News for their role in manufacturing the first Zika DNA Vaccine approved by the FDA for testing in human clinical trials.

Follow this this link or click below to read the full story and watch the video:

KPRC_VGXI

For more information, contact:
Christy Franco, PhD
Business Development Manager
Email
P: 281-466-3790

Logo_QualityTagline_2014_black_transparent

VGXI Celebrates Facility Expansion Grand Opening

U.S. Congressman Kevin Brady visits VGXI to celebrate the grand opening for their new small scale cGMP manufacturing facility, located in The Woodlands, TX.
VGXI Facility Expansion Ribbon Cutting
VGXI Ribbon Cutting, from left: J.J. Hollie, President and CEO of The Woodlands Chamber of Commerce; U.S. Congressman Kevin Brady; Young Park, CEO of GeneOne Life Science; Dorothy Peterson, VP of Operations at VGXI; and Tom Kowalski, President and CEO of THBI.

VGXI, Inc., a leading contract manufacturer of clinical-grade plasmid DNA, announced the completion and grand opening of their facility expansion which includes a new small scale cGMP production plant. U.S. Congressman Kevin Brady attended the Ribbon Cutting Ceremony on May 31, 2016 to celebrate the grand opening and recognize VGXI’s contribution to the global pharmaceutical community. As a contract manufacturing organization since 2003, VGXI has supported the development of new cancer gene therapies and DNA vaccines for critical emerging diseases including Ebola, MERS, and Zika.

The Ribbon Cutting was attended by many representatives of the local and Texas biotechnology communities, including Mr. Tom Kowalski, President and CEO of the Texas Healthcare and Bioscience Institute (THBI), and Ms. Ann Tanabe, CEO of BioHouston.

“VGXI’s clients are developing the next generation of cancer therapies and vaccines,” said Young Park, CEO of VGXI and GeneOne Life Science. “We are proud to support both our client’s needs and the community of The Woodlands with this expansion.”

The new cGMP plant at VGXI is fully equipped to support fermentation capacities from 10L to 40L, and full scale purification of clinical-grade plasmid DNA. Combined with VGXI’s existing 500L scale production facility, the second cGMP plant provides greater manufacturing capacity as well as flexibility for multiple client campaigns to run in parallel. Ultimately, this expansion enables VGXI to continue to meet the growing global demand for DNA-based pharmaceuticals.

ABOUT VGXI, INC.

With over 15 years of experience, VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services for DNA vaccine and gene therapy research. The company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for clinical trials in the US, EU, Asia and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CMO of GeneOne Life Science, Inc.

ABOUT GENEONE LIFE SCIENCE

GeneOne Life Science Inc. (KRX:011000) is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world.

Cautionary Factors That May Affect Future Results

Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

View the official release on PRweb.com

Media Contact:
Christy Franco, PhD
Business Development Manager
Email
P: 281-466-3790
Logo_QualityTagline_2014_black_transparent

Come See Us at the 2016 BIO International Convention

Come by Booth #5533 to meet us and find out more about VGXI’s process and services!
We also welcome requests for partnering meetings during the conference.

 

Biotechnology Industry Organization International Convention
June 6-9, 2015
Moscone Convention Center
San Francisco, CA

 

Not yet registered? Follow the link below for registration information.


View our poster presented at the ASGTC 2016 Annual Meeting

Did you miss us at ASGCT? Download our poster at the link below:

Challenges of Production of Nanoplasmid™ with Large Gene insert using the HyperGRO™ Fermentation Process

Presented on Friday, May 6, 2016 from 6:00 pm – 8:00 pm
Session Information:
Vector and Cell Engineering/Manufacturing II
Location: Exhibit Hall C & B South
Abstract #712

American Society of Gene & Cell Therapy 2016 Annual Meeting
May 4-7th, 2015
Marriott Wardman Park Hotel
Washington DC

Meet us at the ASGCT 2016 Annual Meeting and see our poster #712

American Society of Gene & Cell Therapy 2016 Annual Meeting
May 4-7th, 2015
Marriott Wardman Park Hotel
Washington DC

“Challenges of Production of NanoPlasmid with Large Gene insert using the HyperGRO™ Fermentation Process”

Session Information:
Vector and Cell Engineering/Manufacturing II
Friday, May 6, 2016 from 6:00 pm – 8:00 pm
Location: Exhibit Hall C & B South
Abstract #712